Moving FAST to Treat Angelman Syndrome
b'
The effects of Angelman Syndrome (AS) on young children are debilitating. From an early age, they face an uphill battle with this neurogenetic disease\\u2019s unrelenting symptoms, including seizures, cognitive impairments, and loss of motor function.\\xa0
It can also be tough on caretakers \\u2013 just ask Dr. Allyson Berent and Jennifer Panagoulias. They both have personal connections to this disease, which in Dr. Berent\\u2019s case led to her creating the Foundation for Angelman Syndrome Therapeutics (FAST) in 2008. Today, Panagoulias, whose niece has AS, serves as their head of Regulatory and Policy, tasked with the responsibility to find a path that will develop treatments to improve the quality of life for both patients and caregivers. \\xa0
Join Jennifer as we discuss the origins of FAST, the science behind Angelman Syndrome, the crucial role outside partnerships have played in research, and what\\u2019s in the pipeline for potential therapeutics.
Show Notes\\xa0
- \\n
- \\nFoundation for Angelman Syndrome Therapeutics\\xa0 \\n
- \\nASOs Rescue Brain Rhythms, Sleep Patterns in Angelman Mouse Model\\xa0 \\n
- \\nA Big Year for Angelman Syndrome\\xa0 \\n
- \\nAntisense Therapies and Angelman\'s Syndrome\\xa0 \\n
- \\nUnsilencing Quincy\\xa0 \\n
- \\nThe Quest to Cure Quincy\\xa0 \\n
- \\nDevelopment of Potential Outcome Measures for AS Clinical Trials \\u2013 Angelman Syndrome Foundation\\xa0
\\xa0 \\n